Dietary tweak shows promise for fatty liver management
NCT ID NCT05291104
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether changing the amount of methyl donor nutrients (like folate and choline) in the diet could help people with non-alcoholic fatty liver disease (NAFLD). The goal was to reduce liver fat and improve liver function. 51 participants completed the study, and researchers measured changes in liver fat, body fat, and blood markers. The approach focuses on managing the disease through nutrition rather than curing it.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
51 people
The number who actually took part.
- Started
-
Apr 2022
- Finished
-
Jul 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
20 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * NAFLD/NASH patients * Folate levels in plasma \< 6 ng/mL or choline levels in plasma \< 5 micromol per liter * Folate intake \< estimated average requirement or choline intake \< 50% adequate Intakes * Homocysteine levels in plasma \> 9 micromol per liter Exclusion Criteria: * Asymptomatic carrier of hepatitis B and C * Liver disease except NAFLD * Taking drugs that causes fatty liver * Inflammation about stomach or intestines * Pregnancy * Cancer except liver cancer * Heart disease, vascular disease, or psychosis * Intake alcohol over 100 g or unaccessible intake alcohol
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Non-alcoholic fatty liver disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Taipei Hospital, Ministry of Health and Welfare
New Taipei City, 242, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Underactive thyroid may worsen liver scarring in fatty liver disease
- Can one workout a week melt liver fat?
- Ten-Year liver study asks: what makes fatty liver disease progress?
- Can a liver drug also protect the heart? study tests ursodeoxycholic acid in fatty liver disease
- Ketogenic diet vs mediterranean diet: which better reshapes metabolism?
- Can a simple scan reveal hidden liver damage in diabetes patients?